Introduction
Peroxisome proliferators-activated receptors (PPAR) are members of the nuclear receptor superfamily of ligand-activated transcription factors. Three isoforms, PPARa, PPARb/d and PPARg, are encoded by three genes that respond to diverse, but distinct, sets of ligands (Michalik et al., 2004) . PPARg has emerged as an attractive target for cancer therapy because of its association with many human cancers such as colon, thyroid, breast and prostate (Michalik et al., 2004) . PPARg is abundant in adipose tissues and is also expressed at a lower level in the skeletal muscles, liver, heart, intestine, vascular smooth muscle, lung, breast, colon and prostate. Interestingly abundant PPARg expression has been detected in different tumors such as transformed human B lymphocyte and myeloid cells lines, astrocytomas (Chattopadhyay et al., 2000) , glioblastoma (Nwankwo and Robbins, 2001; Morosetti et al., 2004) and neuroblastoma (Han et al., 2001) .
The role of PPARg in tumor development is controversial. It has been suggested that PPARg is a tumor suppressor, because ligands that activate PPARg promote growth inhibition and apoptosis in cancers of breast Mehta et al., 2000; Kim et al., 2006) , colon , liposarcoma (Tontonoz et al., 1997) and neuroblastoma (Cellai et al., 2006 (Cellai et al., , 2010 . However, it has been suggested the anti-tumor effect induced by such PPARg ligands occurs via a PPARgindependent pathway without the presence of the PPARg receptors (Abe et al., 2002; Lecomte et al., 2008) . Alternatively, several lines of evidence suggest that activated PPARg is not a tumor suppressor, but rather functions as an oncogene. First, expression of PPARg is higher in human prostate cancer cells than in normal prostate tissues (Han and Roman, 2007) . Second, PPARg exhibits a pro-tumor effect in mice bearing a mutation in the APC tumor suppressor gene, because PPARg agonizts increase the frequency and size of colon tumors (Lefebvre et al., 1998; Saez et al., 1998) . Third, PPARg antagonists have anticancer effects in other cell lines and mouse models (Cui et al., 2002; Burton et al., 2008) .
MicroRNAs have critical roles in many biological processes including cancer by directly interacting with specific mRNAs through base pairing and then inhibiting expression of the target genes through a variety of molecular mechanisms (Bartel, 2009; Croce, 2009; Ventura and Jacks, 2009 ). The miR-27 family (miR-27a and miR-27b) directly targets PPARg, and it inhibits adipocyte differentiation (Karbiener et al., 2009; Kim et al., 2010) and is induced upon inflammation in macrophages (Jennewein et al., 2010) . Here, we show that miR-27b also targets PPARg in neuroblastoma cells. miR-27b overexpression or PPARg inhibition blocks neuroblastoma growth in vitro and in vivo. This growth inhibition is associated with decreased expression of NHE1, a PPARg target gene, and a reduced inflammatory response. In contrast, PPARg inhibits NHE1 expression, the inflammatory response, and growth of a breast cancer cell line. These results suggest that miR-27b functions as a tumor suppressor, that PPARg promotes tumor formation in neuroblastomas and that cell type-specific regulation of NHE1 by PPARg underlies the difference between the oncogenic and tumor suppressing functions of PPARg in different cell types.
Results

miR-27b inhibits PPARg expression via its 3 0 untranslated region in neuroblastoma
As the miR-27 family (miR-27a and miR-27b) directly targets PPARg in adipocytes and macrophages (Karbiener et al., 2009; Jennewein et al., 2010; Kim et al., 2010) , we examined whether PPARg is a direct target of miR-27b in a cancer context. Luciferase reporter plasmids containing the wild-type 3 0 untranslated region sequence of PPARg or a deletion mutant (lacking the 8bp seed sequence) were transfected into the SK-N-AS neuroblastoma cancer cell line with miR-27b or an antisense RNA against miR-27b (as-miR-27b). PPARg luciferase activity of the wild-type reporter is reduced fivefold upon miR-27b overexpression, whereas it is increased by 60% upon miR-27b inhibition (Figure 1a ). In contrast, no changes in PPARg luciferase activity are observed in the mutant reporter plasmid upon overexpression of miR-27b or as-miR-27b. As expected, antisense-mediated inhibition of either miR-27a or miR-27b results in increased levels of PPARg mRNA (Figure 1b ). In addition, PPARg protein levels are decreased upon overexpression of miR-27b and increased upon addition of antisense against miR-27b ( Figure 1c ). Lastly, in 10-day-old tumors generated by injection of SK-N-AS cells in a nude mice, PPARg mRNA expression is reduced threefold in tumors injected intratumoral with miR-27b, but not with the control miRNA ( Figure 1d ). Thus, miR-27b inhibits PPARg expression in neuroblastomas cells.
miR-27b inhibits neuroblastoma cell growth in vitro and tumor growth in mouse xenografts
We investigated the role of miR-27b in neuroblastoma cell growth by overexpressing either miR-27b or its antisense RNA. Overexpression of miR-27b or miR-27a inhibits cell growth, whereas overexpression of as-miR-27b or as-miR-27a increases cell growth (Figures 2a). More importantly, in mouse xenografts involving the neuroblastoma cell line, administration of four cycles of miR-27b, but not a control miRNA, strongly reduces tumor growth, whereas tumor growth is enhanced by treatment with as-miR-27b ( Figure 2b ). These observations are indicative of a tumor suppressive role for miR-27b in neuroblastomas, and they are in accord with studies in other types of cancer. Specifically, miR-27b functions as a tumor suppressor gene in breast cancer, and it is highly expressed in human normal breast tissues (Lu et al., 2005) but less expressed in breast cancer tissues (Tsuchiya et al., 2006) . In addition, miR-27b expression is suppressed in anaplastic thyroid cancer (Braun et al., 2010) .
miR-27b levels are reduced in neuroblastoma tissues
To examine whether the tumor-suppressor effects of miR-27b in neuroblastoma cell lines are relevant to the human disease, we measured miR-27b RNA levels in tissue samples from human patients. In all, nine cases miR-27b regulates PPARc in cancer J-J Lee et al tested, miR-27b levels in neuroblastoma tissue were two to threefold lower than in the adjacent non-cancer tissue ( Figure 2c ). Thus, reduced levels of miR-27b are associated with neuroblastoma.
PPARg has a tumor-promoting role in neuroblastoma
The functional role of PPARg activation during cancer development remains controversial, in part because the experiments have been performed with PPARg agonists or antagonists that may mediate their effects through non-PPARg mechanisms (see Introduction). To avoid this problem, we inhibited expression of the PPARg gene by an siRNA and found that this resulted in reduced cell viability (Figure 2a ). In accord with these experiments, treatment of these neuroblastoma cells with the PPARg antagonist GW9662 inhibits cell growth in vitro ( Figure 2d ) and in mouse xenografts (Figure 2e ). In addition, GW9662 inhibits growth of a different neuroblastoma cell line (SK-N-SH; Supplementary Figure 1 ). Lastly, as mentioned above, miR-27b acts as a tumor suppressor, providing an independent line of evidence that reduction of PPARg levels is associated with reduced cancer cell growth. Collectively these observations strongly suggest that PPARg has a growth-stimulating and tumor-promoting role in neuroblastoma cells.
PPARg activates NHE1 in neuroblastoma cells
Activation of the pH regulator NHE1 causes tumors to become more acidic extracellularly and more alkaline intracellularly even during the early stages of neoplastic progression, and hence NHE1 activation is tumor promoting (Hagag et al., 1987; Ober and Pardee, 1987; Siczkowski et al., 1994; Reshkin et al., 2000) . Indeed, si-RNA-mediated inhibition of NHE1 expression results in reduced growth of SK-N-AS neuroblastoma cells (Figure 2a ). NHE1 expression is directly regulated by binding of PPARg to target sites in the NHE1 promoter, and activated PPARg inhibits NHE1 expression in breast cancer cell lines Venkatachalam et al., 2009 ). These observations are consistent with a number of studies concluding that PPARg has anti-tumor effects in breast cancer Mehta et al., 2000; Girnun et al., 2002; Kim et al., 2006; Kumar et al., 2009) . We independently confirmed the anti-tumor effects of PPARg in breast cancer cells using an isogenic model of cellular transformation involving non-transformed mammary epithelial cells (MCF-10A) (Soule et al., 1990) containing ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (Aziz et al., 1999) . Treatment of such cells with tamoxifen rapidly induces Src, and morphological transformation is observed within 24-36 h Iliopoulos et al., 2009) , thereby making it possible to kinetically follow the transition between non-transformed and transformed cells. In this isogenic model, siRNA-mediated inhibition of PPARg or exogenous expression of miR-27b results in increased tumorigenicity (colonies growing in soft agar; Figure 3a ) and invasive growth (MATRIGEL assay; Figure 3b ). Furthermore, tumors derived from these transformed ER-Src cells in mouse xenografts grow more quickly upon injection of siRNA against PPARg (Figure 3c ). Similar effects of miR-27b on reducing PPARg expression ( Figure 3d ) and increasing invasive growth (Figure 3e ) are observed in two other breast cancer cells lines (MDA-MB-231 and MDA-MB-468).
In contrast to the results in breast cancer cells, several lines of evidence indicate that PPARg activates NHE1 expression in neuroblastoma cells. First, expression of as-miR-27b causes increased NHE1 expression ( Figure 4a ) along with increased PPARg expression ( Figures 1b and c) in cell culture. Conversely, expression of miR-27b in mouse xenografts reduces NHE1 (Figure 4b ) and PPARg expression ( Figure 1d ). Second, treatment of neuroblastoma cells with siRNA against PPARg causes a fourfold decrease in NHE1 expression levels (Figure 4c ). Third, the PPARg antagonist GW9662 inhibits both PPARg and NHE1 expression in cell culture (Figure 4d ) and in mouse xenografts (Figure 4e ). Taken together, these observations suggest that PPARg can activate or inhibit NHE1 expression in a cell type-specific manner, and that the differential regulation of NHE1 expression accounts for the opposing tumor-promoting or tumor-inhibiting effects in these different cell types.
miR-27b and PPARg regulate the inflammatory response in neuroblastoma cells
The inflammatory transcription factor nuclear factor-kB (NF-kB) physically interacts with PPARg (Chung et al., 2000) , and there is a great deal of evidence linking NF-kB and inflammation to cancer (Balkwill and Mantovani, 2001; Karin, 2006; Naugler and Karin, 2008; Iliopoulos et al., 2009) . We therefore examined the effect of miR-27 and PPARg on the inflammatory response. Inhibition of miR-27b in SK-N-AS neuroblastoma cells increases mRNA levels of four inflammatory factors (interleukin (IL)-1A, Janus kinase 2, IL-6 and IL-1B), whereas expression of miR-27b results in decreased expression ( Figure 5a ). In addition, mRNA levels of these inflammatory factors are strongly reduced upon siRNA-mediated ( Figure 5a ) or pharmacological inhibition (GW9662) of PPARg (Figure 5b) . Importantly, the increased expression of inflammatory factors upon (Figure 5a ), suggesting that the effects of miR-27b are mediated through PPARg. In accord with these observations, tumors harvested from the mice either treated with GW9662 or with miR-27b
show significantly lower NF-kB activity and reduced IL-6 mRNA expression relative to control groups (Figure 5c ). Lastly, neuroblastoma cell growth is inhibited upon treatment with an NF-kB inhibitor (BAY-117082; Figure 5d ) at concentrations that do Figure 2) . Thus, miR-27b and PPARg regulate the inflammatory response in neuroblastoma cells.
Discussion
Our study identifies a molecular pathway important for growth and tumor progression of neuroblastoma cells ( Figure 6 ). Specifically, miR-27b functions as a tumor suppressor by directly inhibiting the expression of PPARg. Inhibition of PPARg by miR-27b, si-RNA or a pharmacological antagonist reduces expression of NHE1 (presumably by direct binding to the promoter region) and the inflammatory response (by an unknown mechanism). Furthermore, inhibition of PPARg results in reduced cell growth in vitro and tumor growth in mouse xenografts, indicating that PPARg functions as a tumor-promoting factor in neuroblastomas. In accord with this tumor-promoting function, PPARg stimulates NHE1 expression and inflammation, both of which are linked to tumor progression in multiple cell types. Our results do not exclude additional cancer-related functions for miR-27b or for PPARg in neuroblastoma, and indeed these are likely.
Our study also provides new insights on how a transcription factor can act either as an oncogene or as a tumor suppressor depending on the cell type. PPARg activates NHE1 expression in neuroblastomas, but it inhibits NHE1 expression in breast cancer cells, and this discordant regulation of NHE1, an oncogenic factor, is linked to tumor suppression in breast cells and tumor promotion in neuroblastomas ( Figure 6 ). There are many examples in which a DNA-binding transcription factor can directly activate or repress genes in a given cell type, or directly activate or repress a given gene in different cell types. We therefore suggest that PPARg has oncogenic or tumor suppressor functions in different cell types by virtue of cell type-specific regulation of NHE1 and perhaps other target genes.
Materials and methods
Cell lines
The neuroblastoma cell line SK-N-AS (American Type Culture Collection, Manassas, VA, USA) was maintained in Dulbecco's modified Eagle's medium media (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA), and penicillin/ streptomycin (Invitrogen) at 37 1C with 5% CO 2 . The breast epithelial cell line MCF-10A cells containing the ER-Src fusion protein was grown in Dulbecco's modified Eagle's medium/ F12 medium supplemented with 5% donor horse serum, 20 ng/ ml epidermal growth factor, 10 mg/ml insulin, 100 mg/ml hydrocortisone, 1 ng/ml cholera toxin and 50 units/ml penicillin/streptomycin, with the addition of puromycin Iliopoulos et al., 2009) . To induce transformation, the Src oncogene was activated by the addition of 1 mM tamoxifen (Sigma, St Louis, MO, USA correct) for 36 h.
Luciferase assays
The firefly luciferase reporter plasmids contained the entire wild-type 3 0 untranslated region of PPARg (Genecopeia Inc., Rockville, MD, USA) or a mutated derivative deleted for the 8 bp seed sequence deleted generated by inverse-PCR (Supplementary Table 1 ). The Renilla plasmids (0.8 mg) were cotransfected into SK-N-AS cells either with 33 nM of as-miR-27b (AM10750, Ambion, Austin, TX, USA), miR-27b (C-300589-05, Dharmacon, Lafayette, CO, USA) or with non-targeting control (NC; PM11440, Ambion) using Lipofectamine 2000 (Invitrogen) to the cells. The PPARg luciferase activity of the luciferase vector construct only (UT) was normalized to one and the other transfection combinations were compared with UT. Cells were harvested 48 h after transfection and assayed using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA).
RNA analysis
RNA was purified by the Trizol method (Invitrogen), treated with RNase-free DNase (Ambion) and reverse transcribed with using SuperScript III RT (Invitrogen) to generate cDNA. RNA levels were determined by SYBR Green-based real-time-PCR of the cDNA, with the level of b-actin used as a loading control. Each sample was run in triplicate, and the data represent the mean ± s.d. of three independent experiments. PCR primers used for these analyses are shown in Supplementary Table 1 .
Western blotting
The total protein (50 mg) from neuroblastoma cells was isolated by standard methods in radioimmuno precipitation assay buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium, deoxycholate and 0.1% sodium dodecyl sulfate), electrophoretically separated and transferred to nitrocellulose filters. The filters were incubated overnight at 4 1C with anti-PPARg (1:200; ab27649, Abcam Inc., Cambridge, UK) and anti-a-tubulin (1:3000; Clone DM1A, Sigma). The density of the bands was quantified and normalized by the loading control, g-tubulin.
Genetic and pharmacological analysis of cell growth For genetic analysis, SK-N-AS cells seeded in 6-or 12-well plates were transfected with 100 nM miRNAs, antisense (as)-miRNAs or siRNAs using the siPORT NeoFX transfection agent (Ambion) and incubated for 24 h. The number of viable cells was measured at various times after this initial incubation period. For pharmacological analysis, cells were seeded in 24well plates for an initial 20-h incubation period, after which time they were treated with medium containing 15 mM GW9662 (PPARg antagonist; Cayman Chemical, Ann Arbor, MI, USA), a 5 mM BAY-11-72 (NF-kB inhibitor; Sigma) or
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miR-27b regulates PPARc in cancer J-J Lee et al dimethyl sulfoxide (vehicle). Medium containing these inhibitors was changed every 24 h.
Soft agar colony and invasion assays
The soft agar colony and MATRIGEL invasion assays for MCF-10A-ER-Src cells were performed as described previously Hirsch et al., 2010) .
Xenograft experiments SK-N-AS cells (5 Â 10 6 ) were injected into the right flank of nu/nu mice (Charles River Laboratories, Wilmington, MA, USA), all of which developed tumors in 10 days with size of B60 mm 3 . The mice were randomly distributed into groups (typically four mice per group) and treated with miR-27b (100 nM), miRNA negative control (miR-NC; 100 nM), GW9662 (2.5 mg/kg) or dimethyl sulfoxide (0.1 ml/10 g body weight). All treatments were administered intraperitoneally injection every 5 days starting on day 10-25 for four cycles.
Tumor volumes were monitored every 5 days. Tumors were harvested on day 35 for mRNA analysis of PPARg and NHE1 and for measurements of NF-kB activity (ActivELISA kit IMK-503, Imgenex, San Diego, CA, USA). All mouse experiments were performed according to the Institutional Animal Care and Use Committee procedures and guidelines of the Tufts University.
